# Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

> **NCT02330510** · — · COMPLETED · sponsor: **Dr. Sandra E Black** · enrollment: 80 (actual)

## Conditions studied

- Alzheimer's Disease
- Small Vessel Disease White Matter Hyperintensities Subtype
- Vascular Cognitive Impairment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02330510
- **Lead sponsor:** Dr. Sandra E Black
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02330510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02330510, "Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02330510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*